Our very own Alex Powlesland was named the UK’s most prolific inventor by The Chartered Institute of Patent Attorneys (CIPA) in 2016. He’s been named on 33 international patent applications in 2016 alone, the highest number by any British company.
In the same year, our lead molecule, IMCgp100, was granted Orphan Drug Designation by the FDA and moved into Phase I clinical trials for treatment of uveal melanoma, demonstrating the potential value of Immunocore’s proprietary ImmTAC® technology.
In an article by the CIPA, Alex commented “There has been massive financial investment in this technology and our patent strategy is essential in protecting the products that are transforming our patients’ lives”.
As we continue to advance and expand our platform, we have no doubt that Alex and his team will continue to protect our proprietary technology, attracting investment in research and development that ultimately enables us to deliver transformational science that transforms lives.
Find out where you might fit in at Immunocore and search our current opportunities.